Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7LOSK)

• Drug Name: REGN4018 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DM7LOSK

Molecule-Related Drug Atlas

Drug(s) Targeting Ovarian carcinoma antigen CA125 (MUC16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oregovomab	DM06KRC	Ovarian cancer	2C73	Phase 3	[3]
Abagovomab	DMZ0T24	Ovarian cancer	2C73	Phase 2/3	[4]
REGN5668	DMH1UV5	Ovarian cancer	2C73	Phase 1/2	[5]
DMUC-5754A	DMCT4BA	Fallopian tube cancer	2C74	Phase 1	[6]
JCAR020	DM1T8KN	Ovarian cancer	2C73	Phase 1	[7]
PRGN-3005	DMCUE71	Refractory hematologic malignancy	2A85.5	Phase 1	[8]
RG7458	DMW87YE	Ovarian cancer	2C73	Discontinued in Phase 1	[9]

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[11]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[12]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[13]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[14]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[15]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[16]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[17]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[18]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ovarian carcinoma antigen CA125 (MUC16)	TTC1PS3	MUC16_HUMAN	Inhibitor	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03564340) Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
• [2] A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.
• [3] MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129.
• [4] Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62.
• [5] ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
• [6] Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013 May;12(5):329-32.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of Precigen.
• [9] Phase I clinical trail of RG7458 for treating Ovarian cancer. Genentech Inc.
• [10] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [11] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [12] Clinical pipeline report, company report or official report of Genmab.
• [13] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [14] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [15] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [16] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [17] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [18] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [19] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.